MErCuRIC consortia meeting hosted by UNITO, Month 60

The MErCuRIC team of researchers assembled for the Month 60 plenary meeting on November 8th and 9th in Italy. On the 8th the group was met at the Candiolo Cancer Institute (IRCCS) and on the 9th at the Molecular Biotechnology Center of the University of Torino (UNITO).

After an overview and report on the project progress by Coordinator Sandra van Schaeybroeck, Queen’s University Belfast (QUB), Kylie O’Brien of Pintail Limited reminded partners of upcoming and remaining management reporting obligations and deadlines. Usharani Wahengbam, of the University of Oxford, discussed the Phase I trial of the MEK1/2 inhibitor Binimetinib with the cMET/ALK inhibitor Crizotinib in mCRC+. Then, Manuel Salto-Tellez shared the latest in digital pathology from QUB, followed by an update on the optimized Agilent panel and validation. Federica di Nicolantonia of UNITO also updated the team on the genomic analysis of tumour DNA (ctDNA) from MErCuRIC patients. As for the biorepository and sample distribution, Coordinator Sandra van Schaeybroeck led a discussion on the further analysis of the biosamples from MErCuRIC. BHSCT’s Ruth Boyd and Pintail’s Kylie O’Brien brought the group up-to-date with the dissemination work on MErCuRIC including the Public and Patient Involvement (PPI) in research activities. Vlad Popovici, Masarykova Univerzita presented the latest bioinformatics analysis and status of the data management system. There were also sessions for focussed discussions on the pre-clinical and translational advances and abstracts for future conferences and publications. The action points were reviewed and discussed before the end of the meeting.

Thanks to our hosts UNITO for the warm hospitality!

New Website Launched

Thank you very much for visiting our new website for the MErCuRIC project.

We’ll be updating the site over the next few weeks.